Nifty
:
25693.70
Sensex
:
83580.40
50.90 (0.20%)
266.47 (0.32%)
Nifty
Sensex
:
:
25693.70
83580.40
50.90 (0.20%)
266.47 (0.32%)

Marksans Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
50/99

BSE: 524404 | NSE: MARKSANS

NSE BSE
177.36
06-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  179.57
  •  179.57
  •  171.7
  •  179.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1047646
  •  184134052.86
  •  276.4
  •  156

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,027.80
  • 22.58
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,384.66
  • 0.45%
  • 3.03

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 43.87%
  • 1.92%
  • 28.98%
  • FII
  • DII
  • Others
  • 8.13%
  • 4.41%
  • 12.69%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.37
  • 13.77
  • 12.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.85
  • 9.25
  • 9.27

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.10
  • 10.03
  • 12.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.57
  • 17.45
  • 23.68

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.82
  • 3.22
  • 3.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.75
  • 11.44
  • 14.51

Earnings Forecasts:

(Updated: 31-01-2026)
Description
2024
2025
2026
2027
Adj EPS
8.4
8.9
10.83
12.4
P/E Ratio
21.11
19.93
16.38
14.30
Revenue
2622.84
2853.36
3295.88
3782.25
EBITDA
528.64
545.37
648
762.48
Net Income
380.58
403.8
471.53
562.07
ROA
12.86
11.2
11.6
12.3
P/B Ratio
3.26
2.87
2.52
2.21
ROE
16.8
14.64
15.4
15.8
FCFF
65.16
348.55
332.5
421.4
FCFF Yield
0.93
4.98
4.75
6.02
Net Debt
-383.04
-950.35
-1181.6
-1466.75
BVPS
54.44
61.81
70.42
80.43

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
754.43
681.85
10.64%
720.41
641.92
12.23%
619.99
590.62
4.97%
708.46
560.01
26.51%
Expenses
593.69
551.35
7.68%
575.92
495.11
16.32%
519.87
462.18
12.48%
582.70
450.37
29.38%
EBITDA
160.74
130.50
23.17%
144.49
146.81
-1.58%
100.12
128.44
-22.05%
125.75
109.64
14.69%
EBIDTM
21.31%
19.14%
20.06%
22.87%
16.15%
21.75%
17.75%
19.58%
Other Income
20.14
36.11
-44.23%
21.57
-0.07
-
5.64
14.95
-62.27%
16.52
16.53
-0.06%
Interest
5.94
2.67
122.47%
5.81
2.63
120.91%
6.06
2.92
107.53%
3.44
4.84
-28.93%
Depreciation
24.33
20.69
17.59%
26.92
19.51
37.98%
23.10
20.44
13.01%
22.74
21.05
8.03%
PBT
150.62
143.26
5.14%
133.33
124.60
7.01%
76.60
120.02
-36.18%
116.09
100.28
15.77%
Tax
36.93
38.19
-3.30%
34.20
26.84
27.42%
18.40
30.95
-40.55%
25.37
22.63
12.11%
PAT
113.69
105.07
8.20%
99.14
97.76
1.41%
58.20
89.07
-34.66%
90.73
77.64
16.86%
PATM
15.07%
15.41%
13.76%
15.23%
9.39%
15.08%
12.81%
13.86%
EPS
2.50
2.31
8.23%
2.17
2.13
1.88%
1.29
1.96
-34.18%
2.00
1.73
15.61%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
2,803.29
2,622.84
2,177.41
1,852.14
1,490.84
1,376.18
1,134.21
1,000.07
912.69
767.16
893.33
Net Sales Growth
13.29%
20.46%
17.56%
24.23%
8.33%
21.33%
13.41%
9.57%
18.97%
-14.12%
 
Cost Of Goods Sold
1,211.85
1,143.74
1,038.12
921.36
716.81
595.05
567.83
498.01
523.13
458.74
509.69
Gross Profit
1,591.44
1,479.10
1,139.29
930.78
774.02
781.13
566.38
502.07
389.57
308.42
383.63
GP Margin
56.77%
56.39%
52.32%
50.25%
51.92%
56.76%
49.94%
50.20%
42.68%
40.20%
42.94%
Total Expenditure
2,272.18
2,094.21
1,718.83
1,512.82
1,231.96
1,036.58
941.96
867.92
834.31
734.24
760.91
Power & Fuel Cost
-
40.08
36.94
24.50
18.59
16.42
14.38
14.34
11.83
13.27
12.58
% Of Sales
-
1.53%
1.70%
1.32%
1.25%
1.19%
1.27%
1.43%
1.30%
1.73%
1.41%
Employee Cost
-
350.30
293.64
239.37
220.30
197.32
168.42
159.07
147.75
149.70
122.42
% Of Sales
-
13.36%
13.49%
12.92%
14.78%
14.34%
14.85%
15.91%
16.19%
19.51%
13.70%
Manufacturing Exp.
-
140.08
94.76
96.47
12.73
127.47
113.32
77.14
59.90
47.34
50.44
% Of Sales
-
5.34%
4.35%
5.21%
0.85%
9.26%
9.99%
7.71%
6.56%
6.17%
5.65%
General & Admin Exp.
-
117.60
93.90
52.79
37.74
50.67
45.52
51.03
42.51
37.52
36.01
% Of Sales
-
4.48%
4.31%
2.85%
2.53%
3.68%
4.01%
5.10%
4.66%
4.89%
4.03%
Selling & Distn. Exp.
-
256.64
127.31
133.19
119.05
33.54
32.15
68.36
49.14
27.66
29.77
% Of Sales
-
9.78%
5.85%
7.19%
7.99%
2.44%
2.83%
6.84%
5.38%
3.61%
3.33%
Miscellaneous Exp.
-
45.77
34.16
45.14
106.73
16.10
0.34
-0.01
0.05
0.00
29.77
% Of Sales
-
1.75%
1.57%
2.44%
7.16%
1.17%
0.03%
0.00%
0.01%
0%
0%
EBITDA
531.10
528.63
458.58
339.32
258.88
339.60
192.25
132.15
78.38
32.92
132.42
EBITDA Margin
18.95%
20.15%
21.06%
18.32%
17.36%
24.68%
16.95%
13.21%
8.59%
4.29%
14.82%
Other Income
63.87
70.38
50.42
59.31
41.85
6.69
0.33
4.62
8.47
18.85
12.72
Interest
21.25
11.66
11.20
9.13
8.45
7.99
8.75
9.66
10.22
6.78
10.16
Depreciation
97.09
83.39
74.27
51.85
44.78
36.15
26.66
22.80
26.84
30.09
28.13
PBT
476.64
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Tax
114.90
121.35
108.63
72.33
60.70
63.63
36.42
23.87
14.00
3.56
24.11
Tax Rate
24.11%
24.08%
25.65%
21.42%
24.52%
21.06%
23.17%
22.88%
28.11%
23.89%
22.56%
PAT
361.76
380.58
313.69
266.31
184.56
235.94
117.02
76.46
32.94
8.83
78.51
PAT before Minority Interest
360.32
382.62
314.89
265.32
186.81
238.54
120.75
80.44
35.80
11.33
82.74
Minority Interest
-1.44
-2.04
-1.20
0.99
-2.25
-2.60
-3.73
-3.98
-2.86
-2.50
-4.23
PAT Margin
12.90%
14.51%
14.41%
14.38%
12.38%
17.14%
10.32%
7.65%
3.61%
1.15%
8.79%
PAT Growth
-2.11%
21.32%
17.79%
44.29%
-21.78%
101.62%
53.05%
132.12%
273.05%
-88.75%
 
EPS
7.98
8.40
6.92
5.88
4.07
5.21
2.58
1.69
0.73
0.19
1.73

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,466.91
2,065.05
1,745.16
1,202.27
886.50
636.01
542.48
470.86
433.43
454.32
Share Capital
45.32
45.32
45.32
40.93
40.93
40.93
40.93
40.93
40.93
53.43
Total Reserves
2,421.60
2,019.74
1,699.85
1,068.24
845.56
595.08
501.55
429.93
392.50
400.89
Non-Current Liabilities
272.91
205.20
84.33
57.05
23.70
24.15
17.14
15.64
16.07
-1.91
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
5.92
4.56
3.25
1.86
2.11
1.47
1.36
1.08
0.96
0.00
Current Liabilities
477.34
389.85
340.99
380.08
298.97
228.75
232.62
234.68
296.06
259.43
Trade Payables
305.70
268.28
230.60
200.08
168.66
110.33
106.07
77.83
161.78
118.98
Other Current Liabilities
117.17
70.62
42.20
96.80
79.69
58.86
20.90
10.08
0.71
0.68
Short Term Borrowings
23.09
29.09
41.59
41.29
18.74
18.84
99.91
117.41
109.71
87.89
Short Term Provisions
31.39
21.86
26.60
41.92
31.88
40.72
5.74
29.36
23.85
51.88
Total Liabilities
3,239.63
2,680.95
2,190.39
1,660.10
1,228.03
902.02
802.46
730.73
751.81
720.20
Net Block
981.96
775.94
486.31
428.31
309.36
302.72
269.73
279.38
266.98
269.65
Gross Block
1,413.02
1,134.80
828.26
726.26
551.92
565.39
506.26
495.35
456.49
429.47
Accumulated Depreciation
431.06
358.87
341.95
297.96
242.56
262.67
236.54
215.97
189.52
159.82
Non Current Assets
1,035.51
818.46
515.09
435.04
325.20
308.45
271.02
280.19
267.92
280.06
Capital Work in Progress
27.11
9.42
9.87
2.57
11.68
0.00
0.00
0.00
0.36
0.00
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
26.27
32.94
18.91
4.16
4.16
5.73
1.29
0.82
0.59
10.41
Other Non Current Assets
0.17
0.17
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
2,204.12
1,862.49
1,675.30
1,225.07
902.82
593.59
531.44
450.54
483.88
440.15
Current Investments
0.74
26.99
0.54
0.44
0.26
0.00
0.00
0.00
0.00
0.00
Inventories
845.52
617.94
484.74
424.44
404.32
241.84
293.25
218.12
190.09
167.79
Sundry Debtors
540.04
453.18
416.85
394.78
271.95
243.35
176.60
176.91
247.58
217.29
Cash & Bank
704.21
673.58
714.96
349.26
212.18
93.73
33.54
39.88
25.16
35.30
Other Current Assets
113.61
30.98
22.74
24.36
14.11
14.66
28.06
15.63
21.05
19.76
Short Term Loans & Adv.
81.20
59.82
35.48
31.79
0.00
3.40
0.00
0.00
20.96
19.76
Net Current Assets
1,726.78
1,472.64
1,334.31
844.98
603.85
364.83
298.82
215.86
187.82
180.71
Total Assets
3,239.63
2,680.95
2,190.39
1,660.11
1,228.02
902.04
802.46
730.73
751.80
720.21

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
206.66
230.41
237.41
99.26
178.59
233.33
27.40
50.09
14.06
30.80
PBT
503.97
423.53
337.65
247.51
302.16
157.17
104.31
49.80
14.90
106.85
Adjustment
69.37
55.42
74.24
35.31
56.57
42.04
31.88
43.99
26.58
39.63
Changes in Working Capital
-240.77
-126.19
-111.47
-110.70
-131.61
59.12
-81.79
-36.23
-6.04
-88.14
Cash after chg. in Working capital
332.56
352.76
300.43
172.12
227.12
258.33
54.40
57.56
35.44
58.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-125.90
-122.35
-63.01
-72.86
-48.53
-25.00
-27.00
-7.46
-21.37
-27.54
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-49.01
-140.84
-259.21
-84.39
-44.85
-59.58
-13.48
-38.81
-20.73
-123.01
Net Fixed Assets
-141.06
-91.31
-21.45
-24.09
-28.48
-23.87
-23.07
-5.86
-11.49
-22.01
Net Investments
26.25
-26.45
-29.78
-0.18
-0.26
0.00
0.00
-1.78
-2.85
-163.82
Others
65.80
-23.08
-207.98
-60.12
-16.11
-35.71
9.59
-31.17
-6.39
62.82
Cash from Financing Activity
-65.15
-68.73
197.83
79.51
-15.29
-113.55
-20.78
3.38
-3.47
-57.75
Net Cash Inflow / Outflow
92.51
20.84
176.03
94.38
118.46
60.19
-6.86
14.67
-10.14
-149.96
Opening Cash & Equivalents
403.28
382.44
206.41
112.03
93.73
33.54
39.72
25.05
35.30
185.27
Closing Cash & Equivalent
495.79
403.28
382.44
206.41
212.18
93.73
32.85
39.72
25.16
35.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
54.44
45.57
38.51
27.10
21.66
15.54
13.25
11.50
10.59
10.79
ROA
12.93%
12.93%
13.78%
12.94%
22.40%
14.17%
10.49%
4.83%
1.54%
11.86%
ROE
16.89%
16.53%
18.59%
18.72%
31.33%
20.49%
15.88%
7.92%
2.59%
20.45%
ROCE
22.50%
22.40%
22.89%
23.82%
39.76%
25.57%
18.51%
10.60%
3.99%
23.16%
Fixed Asset Turnover
2.16
2.33
2.62
2.42
2.49
2.12
2.00
1.92
1.73
2.46
Receivable days
65.99
69.35
72.63
78.56
67.57
67.57
64.51
84.88
110.59
81.87
Inventory Days
97.24
87.89
81.36
97.65
84.73
86.10
93.32
81.63
85.14
60.86
Payable days
91.59
87.70
85.31
93.88
85.57
45.09
38.48
55.10
65.56
54.58
Cash Conversion Cycle
71.65
69.54
68.67
82.33
66.73
108.58
119.35
111.40
130.17
88.15
Total Debt/Equity
0.01
0.01
0.02
0.04
0.02
0.03
0.18
0.25
0.25
0.19
Interest Cover
44.22
38.80
37.99
30.31
38.84
18.97
11.80
5.87
3.20
11.52

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Marksans Pharma - Quarterly Results
    6th Feb 2026, 00:00 AM

    Read More
  • Marksans Pharma incorporates wholly owned subsidiaries
    27th Jan 2026, 15:51 PM

    Marksans Pharma (Europe) has been incorporated in Ireland for the purpose of carrying on the business of pharmaceutical products

    Read More
  • Marksans Pharma’s arm gets UK MHRA approval for Cetirizine Dihydrochloride
    20th Nov 2025, 16:13 PM

    Relonchem in the UK, has received Marketing Authorization for Cetirizine Dihydrochloride

    Read More
  • Marksans Pharma’s arm gets USFDA’s final nod for Loperamide Hydrochloride tablets
    19th Nov 2025, 14:51 PM

    Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute and chronic diarrhea

    Read More
  • Marksans Pharma’s arm gets marketing authorization for two products
    17th Nov 2025, 14:08 PM

    Relonchem has received marketing authorization from UK Medicines & Healthcare products Regulatory Agency

    Read More
  • USFDA completes cGMP inspection at Marksans Pharma’s Goa facility
    10th Nov 2025, 15:20 PM

    At the conclusion of the inspection, the USFDA issued zero from 483 observation

    Read More
  • Marksans Pharma’s arm gets marketing authorization from UK MHRA
    5th Nov 2025, 10:28 AM

    Relonchem has received marketing authorization for its product Exemestane 25mg film-coated tablets

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.